Mechanism of EGER-related cancer drug resistance

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Cancer drug resistance is a major challenge, driven by complex molecular events.
• Epidermal Growth Factor Receptor (EGFR) is a key target in cancer therapy, but resistance mechanisms are not fully understood.
• Gene alterations and signaling pathway dysregulation contribute significantly to therapeutic failure.

Purpose of the Study:

• To comprehensively review literature on Epidermal Growth Factor Receptor (EGFR) gene alterations (mutation, amplification, expression) and downstream signaling.
• To identify molecular mechanisms underlying resistance to EGFR-targeted therapies.
• To explore the role of gene signatures in predicting response to therapy and guiding personalized medicine.

Main Methods:

• Extensive literature review of published studies.
• Analysis of gene mutations, copy number variations, and expression levels of EGFR and related genes (KRAS, BRAF, PIK3CA, PTEN, MEK, AKT).
• Synthesis of findings to understand resistance mechanisms and therapeutic strategies.

Main Results:

• EGFR gene status (mutation, amplification, expression) and downstream pathway alterations are critical determinants of EGFR inhibitor resistance.
• Specific gene signatures (e.g., KRAS, BRAF, PIK3CA, PTEN, MEK, AKT) are associated with response to therapy.
• Multicomponent therapies and drug combinations show potential for overcoming resistance.

Conclusions:

• Identifying molecular regulators of EGFR inhibitor resistance is essential for effective cancer treatment.
• Molecular interaction profiles and gene signatures offer valuable insights for novel therapy discovery.
• This review supports the advancement of personalized cancer medicine through a deeper understanding of drug resistance mechanisms.